{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T12:09:41Z","timestamp":1778501381166,"version":"3.51.4"},"reference-count":18,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2020,2,12]],"date-time":"2020-02-12T00:00:00Z","timestamp":1581465600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>This study aims to assess the in vitro activity of different samples of cefoperazone\/sulbactam (CFP\/SUL) against multidrug-resistant organisms (MDROs). Clinical isolates of extended-spectrum \u03b2-lactamase (ESBL)-Escherichia coli, ESBL-Klebsiella pneumoniae, carbapenem-resistant Acinetobacter baumannii (CR-AB), and carbapenem-resistant Pseudomonas aeruginosa (CR-PA) were collected. The minimum inhibitory concentration (MIC) and time-killing methods were used to assess and compare the in vitro activities of different samples of cefoperazone\/sulbactam (CFP\/SUL) against these MDROs. For ESBL-E. coli, ESBL-K. pneumoniae, and CR-PA, product C had smaller variations than product A and B (p &lt; 0.05). For CR-AB, product B had the largest variation compared to the other two products (p &lt; 0.05). In the time-killing studies, significant differences among the products when used at 16\/16 \u00b5g\/mL were noted for ESBL-E. coli, ESBL-K. pneumoniae, and CR-AB isolates. In conclusion, this study demonstrated the significantly different activity of different products of CFP\/SUL against MDROs.<\/jats:p>","DOI":"10.3390\/antibiotics9020077","type":"journal-article","created":{"date-parts":[[2020,2,14]],"date-time":"2020-02-14T10:09:57Z","timestamp":1581674997000},"page":"77","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["In Vitro Antimicrobial Activity of Various Cefoperazone\/Sulbactam Products"],"prefix":"10.3390","volume":"9","author":[{"given":"Ming-Jen","family":"Sheu","sequence":"first","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Chi Mei Medical Center, Tainan 710, Taiwan"},{"name":"Department of Medicinal Chemistry, Chia Nan University of Pharmacy &amp; Science, Tainan 717, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chi-Chung","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Medical Research; Chi Mei Medical Center; Tainan 710, Taiwan"},{"name":"Department of Food Science, National Chiayi University, Chiayi 717, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9987-1898","authenticated-orcid":false,"given":"Ying-Chen","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Medical Research; Chi Mei Medical Center; Tainan 710, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo-An","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chi Mei Medical Center, Tainan 710, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chun-Cheng","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chi Mei Medical Center, Tainan 710, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shu-Shen","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chi Mei Medical Center, Tainan 710, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yin-Ching","family":"Chuang","sequence":"additional","affiliation":[{"name":"Department of Medicinal Chemistry, Chia Nan University of Pharmacy &amp; Science, Tainan 717, Taiwan"},{"name":"Department of Food Science, National Chiayi University, Chiayi 717, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hung-Jen","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chi Mei Medical Center, Tainan 710, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chih-Cheng","family":"Lai","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan 710, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2020,2,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.4103\/1011-4564.196365","article-title":"Antimicrobial activities of cefoperazone-sulbactam in comparison to cefoperazone against clinical organisms from medical centers in Taiwan","volume":"36","author":"Chiang","year":"2016","journal-title":"J. Med. Sci."},{"key":"ref_2","first-page":"49","article-title":"In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli","volume":"32","author":"Kuo","year":"2009","journal-title":"New Microbiol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.diagmicrobio.2017.02.020","article-title":"Antimicrobial activity of tigecycline and cefoperazone\/sulbactam tested against 18,386 Gram-negative organisms from Europe and the Asia-Pacific region (2013\u20132014)","volume":"88","author":"Pfaller","year":"2017","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/0924-8579(96)00308-1","article-title":"In vitro activity of ampicillin, cefoperazone, their combinations with sulbactam and other antimicrobials: Survey of Russian isolates","volume":"7","author":"Sidorenko","year":"1996","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.jmii.2017.08.026","article-title":"The impact of inoculum size on the activity of cefoperazone-sulbactam against multidrug resistant organisms","volume":"51","author":"Chang","year":"2018","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/IDR.S181201","article-title":"In vitro activity of cefoperazone and cefoperazone-sulbactam against carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa","volume":"12","author":"Lai","year":"2019","journal-title":"Infect. Drug Resist."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1128\/AAC.00350-13","article-title":"Even apparently insignificant chemical deviations among bioequivalent generic antibiotics can lead to therapeutic nonequivalence: The case of meropenem","volume":"58","author":"Agudelo","year":"2014","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"2824","DOI":"10.1128\/AAC.00164-12","article-title":"Quality Assessment of U.S. Marketplace Vancomycin for Injection Products Using High-Resolution Liquid Chromatography-Mass Spectrometry and Potency Assays","volume":"56","author":"Hadwiger","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1128\/AAC.05344-11","article-title":"Product Quality of Parenteral Vancomycin Products in the United States","volume":"56","author":"Nambiar","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10156-012-0437-0","article-title":"Generic antibiotics in Japan","volume":"18","author":"Fujimura","year":"2012","journal-title":"J. Infect. Chemother."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1128\/AAC.03633-14","article-title":"Impact on resistance of the use of therapeutically equivalent generics: The case of ciprofloxacin","volume":"59","author":"Rodriguez","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Zuluaga, A.F., Agudelo, M., Carde\u00f1o, J.J., Rodriguez, C.A., and Vesga, O. (2010). Determination of Therapeutic Equivalence of Generic Products of Gentamicin in the Neutropenic Mouse Thigh Infection Model. PLoS ONE, 5.","DOI":"10.1371\/journal.pone.0010744"},{"key":"ref_13","first-page":"369","article-title":"Evaluation and comparison of in-vitro dissolution profiles for different brands of amoxicillin capsules","volume":"13","author":"Kassaye","year":"2013","journal-title":"Afr. Health Sci."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.diagmicrobio.2016.04.015","article-title":"Bioequivalence and in vitro antimicrobial activity between generic and brand-name levofloxacin","volume":"85","author":"Sun","year":"2016","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.diagmicrobio.2007.12.010","article-title":"In vitro potency evaluations of various piperacillin\/tazobactam generic products compared with the contemporary branded (Zosyn\u00ae, Wyeth) formulation","volume":"61","author":"Jones","year":"2008","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_16","unstructured":"Clinical and Laboratory Standards Institute (2011). Performance Standards for Antimicrobial Susceptibility Testing: Twenty First Informational Supplement: CLSI Document M100 S21, Clinical and Laboratory Standards Institute."},{"key":"ref_17","doi-asserted-by":"crossref","unstructured":"Elcocks, E., and Adukwu, E.C. (2018). Evaluation of Two Sigma Transwab\u00ae Systems for Maintenance of Viability of Pathogenic Candida Spp. Using the Clinical and Laboratory Standards Institute M40-A2 Standard, Cold Spring Harbor Laboratory.","DOI":"10.1101\/321018"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Tang, H.-J., Lai, C.-C., Chen, C.-C., Zhang, C.-C., Weng, T.-C., Yu, W.-L., Chen, H.-J., Chiu, Y.-H., Ko, W.-C., and Chuang, Y.-C. (2017). Cephalosporin-Glycopeptide Combinations for Use against Clinical Methicillin-Resistant Staphylococcus aureus Isolates: Enhanced in vitro Antibacterial Activity. Front. Microbiol., 8.","DOI":"10.3389\/fmicb.2017.00884"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/2\/77\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T08:57:17Z","timestamp":1760173037000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/9\/2\/77"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2,12]]},"references-count":18,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2020,2]]}},"alternative-id":["antibiotics9020077"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics9020077","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2,12]]}}}